• Sickle Cell Disease Association Launches First Patient-powered Registry
  • MaxCyte and NIH Office Partner to Develop Cell Therapy for Sickle Cell Disease
  • Potential Treatment Targeting Nitric Oxide Levels, Olinciguat, Named Orphan Drug by FDA
  • Platform to Diagnose, Monitor SCD Wins Vodafone Wireless Innovation Project Grant
  • Potential Sickle Cell Treatment Altemia Shows Promise in Phase 2 Trial, Data Reports
  • FDA Places Clinical Hold on IND Application for CTX001 for Sickle Cell Disease
  • US ‘Right to Try’ Law Meets with Mix of Praise and Criticism, Including Among Those with Rare Diseases
  • Loss of Cell Defense Mechanism Worsens Sickle Cell Disease Severity, Mouse Study Shows
  • Kids with Sickle Cell Disease Aren’t Receiving Key Vaccines, Michigan Study Finds
  • #ERDC2018 – When Treating Rare Disease Patients, Don’t Overlook Quality of Life, Panel Urges
  • Mutation Associated with Sickle Cell Disease Corrected in Patient’s Stem Cells, MaxCyte Reports
  • Sickle Cell Trait Not Associated with Increased Stroke Risk, Study Suggests